| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/04/2009 | US20090142326 Glycosidase Enzymes |
| 06/04/2009 | US20090142322 Coenzyme Q10 Production in a Recombinant Oleaginous Yeast |
| 06/04/2009 | US20090142303 Methods and compositions for dried cellular forms |
| 06/04/2009 | US20090142296 Method of increasing trafficking of endothelial progenitor cells to ischemia-damaged tissue |
| 06/04/2009 | US20090142272 Pfks as modifiers of the igfr pathway and methods of use |
| 06/04/2009 | US20090142267 Fusogenic properties of saposin c and related proteins and peptides for application to tansmembrane drug delivery systems |
| 06/04/2009 | CA2707187A1 Lactic acid bacterium having effect of lowering blood uric acid level |
| 06/04/2009 | CA2706800A1 Novel use |
| 06/04/2009 | CA2706171A1 Fused indane compound |
| 06/04/2009 | CA2704826A1 Method for producing granulated preparation |
| 06/04/2009 | CA2694572A1 Drug for alleviating motor complications or psychiatric symptoms of parkinson's disease |
| 06/03/2009 | EP2065401A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2065400A2 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 06/03/2009 | EP2065388A1 Pyrazolopyrimidine derivative |
| 06/03/2009 | EP2065384A1 Tricyclic thrombin receptor antagonist |
| 06/03/2009 | EP2065379A1 Benzimidazole compound having gastric acid secretion inhibitory activity |
| 06/03/2009 | EP2065372A1 Antitumor agent for undifferentiated gastric cancer |
| 06/03/2009 | EP2065366A2 HIF hydroxylase inhibitors |
| 06/03/2009 | EP2065053A1 Cell death inhibitor |
| 06/03/2009 | EP2065044A1 Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators |
| 06/03/2009 | EP2065041A1 Use of medium chain triglycerides for the treatment and prevention of Parkinson's disease, Huntington' disease or Amyloid Lateral Sclerosis resulting from reduced neuronal metabolism |
| 06/03/2009 | EP2064951A1 Use of a substituted imidazole, derivatives or salts thereof for the preparation of a medicament for the treatment of a cell proliferative disorder |
| 06/03/2009 | EP1399440B1 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors |
| 06/03/2009 | EP1313737B1 Novel guanidino derivatives as inhibitors of cell adhesion |
| 06/03/2009 | EP1218544B1 TAR RNA binding peptides |
| 06/03/2009 | EP1131426B1 Mage-10 or mage-8 derived hla-a2.1-binding oligopeptides |
| 06/03/2009 | EP1071668B1 5-aminoindeno[1,2-c]pyrazol-4-ones as anti-cancer and anti-proliferative agents |
| 06/03/2009 | EP0772677B1 T cell activation |
| 06/03/2009 | CN101445555A Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions |
| 06/03/2009 | CN101445463A Beta2-adrenergic receptor agonists |
| 06/03/2009 | CN101444624A Medicine for cancer therapy |
| 06/03/2009 | CN101444509A Triple monoamine reuptake inhibitors for the treatment of chronic pain |
| 06/03/2009 | CN100494213C Process for preparing synergistic factor in artificial blood, nucleotide sequence used thereby |
| 06/03/2009 | CN100494185C Novel quaternary ammonium compounds |
| 06/03/2009 | CN100494182C Regulatory factor of tumor necrosis alpha factor |
| 06/02/2009 | US7541443 A humanized antibody for use as immunosuppressants, treating or preventing transplant rejection in human patient; drug screening |
| 06/02/2009 | US7541437 Breast cancer resistance protein (BCRP) and the DNA which encode it |
| 06/02/2009 | US7541378 tert-butyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate; N-benzyl-3-[(4-fluorobenzoyl)amino]-1H-thieno[2,3-c]pyrazole-5-carboxamide; treats a disease caused associated with an altered (disregulated) protein kinase activity e.g cancer, cell proliferative disorders, Alzheimer's disease, viral infections |
| 06/02/2009 | US7541376 3-(3-Fluoro-phenyl)-6-methoxy-1H-indazole-5-carboxylic acid(furan-2-ylmethyl)-amide; 3-Benzo[b]thiophen-2-yl-4-methoxy-1H-indazole-5-carboxylic acid[3-(2-oxo-pyrrolidin-1-yl)-propyl]-amide; Jun amino-terminal kinase (JNK) inhibitor; immunologic disease, inflammatory and neurodegenerative diseases |
| 06/02/2009 | US7541375 Azole derivatives and pharmaceutical compositions containing them |
| 06/02/2009 | US7541369 Amino-derivatives as novel inhibitors of histone deacetylase |
| 06/02/2009 | US7541363 (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione; excellent solubility, stability, bioavailability, dispersing property; adenosine A2 receptor antagonistic activity; treats Parkinson disease, senile dementia, depression, asthma and osteoporosis |
| 06/02/2009 | US7541362 7-(3,4-Dichlorophenyl)-4,7-dihydro-5-methyl-6-(5-phenyl-2-oxazolyl)pyrazolo[1, 5-a]pyrimidine |
| 06/02/2009 | US7541354 Bicyclo-pyrazoles |
| 06/02/2009 | US7541341 2-(4-ethylbenzyl)-5-hydroxymethylphenyl 6-O-ethoxycarbonyl- beta -D-glucopyranoside; for treatment/prevention of hyperglycemia associated with diabetes/obesity |
| 06/02/2009 | US7541339 Par-2-activating peptide derivative and pharmaceutical composition using the same |
| 06/02/2009 | US7541337 Methods and compositions for the treatment of peripheral artery disease |
| 06/02/2009 | US7541336 Prepared by culturing a microorganism belonging to fungi and having ability to produce FKI-1033 substance in a medium; use in agrochemicals, veterinary medicines and pharmaceuticals having an activity of ryanodine binding inhibition, an insecticidal and anthelmintic activity |
| 06/02/2009 | US7541153 Screening a substance interfering in the association of Dedicator of cytokinesis 2 (DOCK2) and engulfment and cell motility 1(ELMO1); drug screening; allergy, autoimmune diseases, GvH, graft rejection |
| 06/02/2009 | US7541027 polyclonal antibodies, monoclonal antibodies, F(ab')2, Fab and single chain Fv; tyrosine at position 1214 in the amino acid sequence of the vascular endothelial growth factor receptor |
| 06/02/2009 | US7541024 A stable polyallylamine hydrochloride polymer crosslinked by epichlorohydrin |
| 06/02/2009 | US7541018 Treatment process using somatostatin analogues |
| 06/02/2009 | CA2474003C Process for the preparation of high purity perindopril and intermediates useful in the synthesis |
| 06/02/2009 | CA2452253C Novel crystal of arylethenesulfonamide derivative and preparation process thereof |
| 06/02/2009 | CA2450787C Active ingredient combination for pharmacological addictive substance or intoxicant therapy |
| 06/02/2009 | CA2434277C Substituted alkylamine derivatives and methods of use |
| 06/02/2009 | CA2425395C Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
| 06/02/2009 | CA2410160C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 06/02/2009 | CA2394606C New modulators of dopamine neurotransmission |
| 06/02/2009 | CA2371728C High dose radionuclide complexes for bone marrow suppression |
| 06/02/2009 | CA2350425C Use of an insulin sensitiser for the treatment of type 2 diabetes mellitus |
| 06/02/2009 | CA2340416C Co-lyophilized complex of a nucleic acid vector and a formulating agent |
| 06/02/2009 | CA2334308C Hyperforin derivatives, the use thereof and formulations containing them |
| 06/02/2009 | CA2321664C Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 06/02/2009 | CA2226548C Lyophilized hepatocyte growth factor preparations |
| 06/02/2009 | CA2190867C Methods for reduced renal uptake of antibody fragments |
| 05/28/2009 | WO2009067105A1 Loadable polymeric particles for enhanced imaging in clinical applications and methods of preparing and using the same |
| 05/28/2009 | WO2009066746A1 Material for preventing tissue adhesion and material for preventing joint contracture |
| 05/28/2009 | WO2009066712A1 Aromatase inhibitor |
| 05/28/2009 | WO2009066655A1 Human antibody capable of inducing apoptosis |
| 05/28/2009 | WO2009066562A1 Differentiation promoter and/or proliferation promoter for erythrocyte stem cells, use of methionine for preventing or treating senile anemia, and compositions containing methionine |
| 05/28/2009 | WO2009065994A1 Use of inductor agents gse24.2 for producing pharmaceutical compositions for treating illnesses relating to cellular senescence |
| 05/28/2009 | WO2009047723A3 Tetrahydroquinoline derivatives for treating post-traumatic stress disorders |
| 05/28/2009 | WO2009047644A3 Method of treating vitamin d insufficiency and deficiency |
| 05/28/2009 | US20090137845 Novel 4-Dedimethylaminotetracycline derivatives |
| 05/28/2009 | US20090137805 N-phenyl-2-pyrimidine-amine derivatives |
| 05/28/2009 | US20090137629 Sigma receptor binding agent containing indanone derivative |
| 05/28/2009 | US20090137604 corticotropin releasing factor receptor antagonists such as 8-(N-butyl-N-(2-butynyl)amino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine, used for the treatment of nervous system, psychological, eating, sleep, and gastrointestinal disorders |
| 05/28/2009 | US20090137597 Novel quinoxalinone derivatives |
| 05/28/2009 | US20090137536 Method for treating and preventing hyperparathyroidism |
| 05/28/2009 | US20090137513 RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA) |
| 05/28/2009 | US20090137512 nucleotide sequence complementary to a target RNA sequence and a second sequence chemically modified so it can no longer act as a guide sequence for mediating RNA interference, having complementarity to said first sequence; cancer, proliferative diseases |
| 05/28/2009 | US20090137511 RNA INTERFERENCE MEDIATED INHIBITION OF PLACENTAL GROWTH FACTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137509 RNA INTERFERENCE MEDIATED INHIBITION OF PROLIFERATION CELL NUCLEAR ANTIGEN (PCNA) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/28/2009 | US20090137508 Treatment of any disease that responds to modulation of gene expression, for example cancer, proliferative, inflammatory, metabolic, autoimmune, neurologic, ocular diseases; in vivo stability and bioavailability |
| 05/28/2009 | US20090137504 Microrna target site blocking oligos and uses thereof |
| 05/28/2009 | US20090137482 Biologically active peptide and agent containing the same |
| 05/28/2009 | US20090137479 Methods of treating and diagnosing laminopathy |
| 05/28/2009 | US20090137477 Treatment of oropharyngeal candidiasis in cancer patients |
| 05/28/2009 | US20090137476 Apo-2 ligand variants and uses thereof |
| 05/28/2009 | US20090137453 Composition comprising at least one oxazoline to inhibit migration of langerhans cells, and uses thereof |
| 05/28/2009 | US20090137040 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
| 05/28/2009 | US20090136980 screening for a therapeutic oligopeptide for treatment of tumor disorders; contacting the tumor with a therapeutically effective amount of a CD10 cleavable prodrug, wherein tumor is comprised of one or more target cells which express CD10 for at least a portion of the target cell life cycle |
| 05/28/2009 | US20090136582 Colloidal magnetic nanobioparticles for cytotoxicity and drug delivery |
| 05/28/2009 | US20090136564 Micelles |
| 05/28/2009 | US20090136539 Methods for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes, conjugated fatty acids, and/or conjugated fatty alcohols |
| 05/28/2009 | US20090136464 Methods and compositions for cell therapy |
| 05/28/2009 | US20090136463 Schwann Cell Bridge Implants and Phosphodiesterase Inhibitors to Stimulate CNS Nerve Regeneration |
| 05/28/2009 | US20090136455 Canine probiotic bifidobacteria pseudolongum |
| 05/28/2009 | US20090136419 parenterally administering a dose of samarium ethylenediaminetetramethylenephosphonic acid (EDTMP); and carboplatin or taxoids; anticarcinogenic, antitumor, and antantiproliferative agents; autoimmune, infectious , metabolic or genetic disorders |